Memantine Treatment of Compulsive Buying

Phase 2

Completed

• Conditions: Compulsive Buying
• Interventions: Drug: Memantine

• Registration Number: NCT00830375
• Lead Sponsor: University of Minnesota

Brief Summary

This is an 8-week, open-labe study of memantine in the treatment of compulsive buying.

Detailed Description

The goal of the proposed study is to evaluate the efficacy of memantine in the treatment of compulsive buying. Sixteen subjects meeting criteria for compulsive buying will receive 8 weeks of open-label memantine. The hypothesis to be tested is that memantine will be effective and well tolerated in patients with compulsive buying. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.

Study Timeline

• Study Start: 2008-12-01
• Study First Submitted: 2009-01-23
• Study First Submitted QC: 2009-01-26
• Study First Posted: 2009-01-27
• Primary Completion: 2010-08-01
• Study Completion: 2010-08-01
• Results First Submitted: 2012-03-01
• Results First Submitted QC: 2012-04-09
• Results First Posted: 2012-05-04
• Status Verified: 2019-07
• Last Update Submitted: 2019-07-10
• Last Update Posted: 2019-07-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

1. men and women age 18-65
2. current CB using the clinician-administered Structured Clinical Interview for Compulsive buying (SCI-CB)
3. buying behavior within 2 weeks prior to enrollment

Exclusion Criteria

1. infrequent buying (i.e. less than one time per week) that does not meet proposed criteria for CB
2. unstable medical illness or clinically significant abnormalities on laboratory tests or physical examination at screen
3. history of seizures
4. myocardial infarction within 6 months
5. current pregnancy or lactation, or inadequate contraception in women of childbearing potential
6. a need for medication other than memantine with possible psychotropic effects or unfavorable interactions;
7. clinically significant suicidality;
8. current Axis I disorder determined by the SCID and SCID-compatible modules for impulse control disorders, except for nicotine dependence
9. lifetime history of bipolar disorder type I or II, dementia, schizophrenia, or any psychotic disorder determined by SCID
10. current or recent (past 3 months) DSM-IV substance abuse or dependence;
11. positive urine drug screen at screening
12. initiation of psychotherapy or behavior therapy within 3 months prior to study baseline
13. previous treatment with memantine
14. treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Memantine	Memantine	10-30mg, memantine

Primary Outcome Measures

Name	Time	Method
Yale Brown Obsessive Compulsive Scale Modified for CB (CB-YBOCS)	from study start to study end (8-weeks) and is Investigator rated	The CB-YBOCS is a reliable and valid, 10-item, clinician-administered scale that rates buying symptoms within the last seven days, on a severity scale from 0 to 4 for each item (total scores range from 0 to 40 with higher scores reflecting greater illness severity). Scores ranging from 0 to 10 reflect minimal or mild symptoms; scores from 11 to 20 suggest moderate symptoms; severe symptoms are associated with scores from 21 to 30; and scores greater than 30 reflect extreme buying symptoms

Trial Locations

Locations (2)

Ambulatory Research Center; 🇺🇸 Minneapolis, Minnesota, United States

University of Minnesota; 🇺🇸 Minneapolis, Minnesota, United States